Thread by @ManniMD1

After ending two weeks on the BMT inpatient service, here is a 🧵 on my favorite BMT CTN trials that I teach to every new fellow/PA/NP/pharmacist/trainee on rounds.

I love these trials, and look forward to the ongoing ones!

(CAVEAT-trials simplified for purpose of 🧵)

#bmtsm

BMT CTN 0201

Peripheral blood VS bone marrow source for unrelated donor transplant for blood cancers

Primary Endpoint= 2 year OS was similar

⬆️chronic GVHD with peripheral blood
⬇️ long term QOL with peripheral blood

pubmed.ncbi.nlm.nih.gov/23075175/

BMT CTN 0102

Autotransplant followed by either non myeloablative allo transplant or a tandem auto for myeloma

Primary Endpoint=3 yr PFS, similar between both arms

⭐️Role for allogenic transplant limited- role of tandem limited now too (see next tweet)

pubmed.ncbi.nlm.nih.gov/21962393/

BMT CTN 0702

Autotransplant followed by either len maint, another auto transplant+len maint, or VRD consolidation followed by len maint in #mmsm

Primary Endpoint= PFS at 38 months, similar in all 3 arms

pubmed.ncbi.nlm.nih.gov/30653422/

Single auto+len maint preferred approach!

BMT CTN 0901

Myeloablative vs Reduced-Intensity for AML/MDS (age less than 65)

Better long-term OS with myeloablative, lower relapse risk despite increase treatment mortality

⭐️For eligible patients, standard of care remains myeloablative transplant

pubmed.ncbi.nlm.nih.gov/28380315/

BMT CTN 1101

Umbilical cord blood versus haplo for leukemia/lymphoma

Primary Endpoint=2 year PFS similar, but worse OS and ⬆️treatment mortality for cord blood

⭐️Haplo preferred route for those without matched sibling or matched unrelated donor!

ncbi.nlm.nih.gov/pmc/articles/P…

I think that is enough for now- I do have another favorite- BMT CTN 1301 comparing methods of GVHD prevention- but that is a complex trial that deserves a thread of its own!

Thanks for reading!
@AaronGoodman33 @BldCancerDoc @rajshekharucms

-END